TRACON Pharmaceuticals Inc (NAS:TCON)

$ 1.26 0.02 (1.63%) Market Cap: 3.38 Mil Enterprise Value: -4.95 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 27/100

Q1 2024 TRACON Pharmaceuticals Inc Earnings Call Transcript
May 14, 2024

$1.97 (-2.48%)

Earnings
Q4 2023 TRACON Pharmaceuticals Inc Earnings Call Transcript
Mar 05, 2024

$3.75 (-0.53%)

Earnings
Q3 2023 TRACON Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2023

$3.2 (+0.95%)

Earnings
TRACON Pharmaceuticals Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Q2 2023 TRACON Pharmaceuticals Inc Earnings Call Transcript
Aug 14, 2023

$5.78 (-9.66%)

Earnings
TRACON Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 TRACON Pharmaceuticals Inc Earnings Call Transcript
May 10, 2023

$14.2 (-0.27%)

Earnings
Q4 2022 TRACON Pharmaceuticals Inc Earnings Call Transcript
Mar 08, 2023

$27.6 (-8.00%)

Earnings
Q3 2022 TRACON Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2022

$33.8 (+9.03%)

Earnings
Q2 2022 TRACON Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2022

$41.4 (+10.11%)

Earnings
Q1 2022 TRACON Pharmaceuticals Inc Earnings Call Transcript
May 11, 2022

$35.6 (-1.66%)

Earnings
Q4 2021 TRACON Pharmaceuticals Inc Earnings Call Transcript
Mar 15, 2022

$54 (+1.50%)

Earnings
Q3 2021 TRACON Pharmaceuticals Inc Earnings Call Transcript
Nov 03, 2021

$73.2 (-1.88%)

Earnings
TRACON Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Q2 2021 TRACON Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2021

$73.2 (-2.66%)

Earnings
Q1 2021 TRACON Pharmaceuticals Inc Earnings Call Transcript
May 05, 2021

$134 (-7.20%)

Earnings
Q4 2020 TRACON Pharmaceuticals Inc Earnings Call Transcript
Feb 25, 2021

$180 (-4.26%)

Earnings
Q3 2020 TRACON Pharmaceuticals Inc Earnings Call Transcript
Nov 10, 2020

$110.8 (-0.18%)

Earnings
Q2 2020 TRACON Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2020

$39.2 (+1.03%)

Earnings
TRACON Pharmaceuticals Inc Key Opinion Leader Webinar On Envafolimab For The Treatment Of Sarcoma Call Transcript
Jul 17, 2020
Q1 2020 TRACON Pharmaceuticals Inc Earnings Call Transcript
May 13, 2020

$45 (+4.17%)

Earnings
Q4 2019 TRACON Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2020

$59 (-2.96%)

Earnings
TRACON Pharmaceuticals Inc Call to Discuss Collaborative Partnership Agreement with 3D Medicines (Beijing) Co Ltd and Jiangsu Alphamab Biopharmaceuticals Co Ltd Transcript
Dec 20, 2019
Q3 2019 TRACON Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2019

$89.8 (+6.30%)

Earnings
Q2 2019 TRACON Pharmaceuticals Inc Earnings Call Transcript
Aug 07, 2019

$82.46 (-0.53%)

Earnings
Q1 2019 TRACON Pharmaceuticals Inc Earnings Call Transcript
May 14, 2019

$136.5 (+1.88%)

Earnings
Q4 2018 TRACON Pharmaceuticals Inc Earnings Call Transcript
Feb 28, 2019

$224 (+0.90%)

Earnings

TRACON Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 12:30PM GMT

Release Date Price: $11.82 (-7.64%)

Transcript

Unidentified Participant

Hello, good morning, everyone. I'm [James Stamos], I'm part of Maury Raycroft's team here at Jefferies. I'm happy to introduce CEO, Charles Theuer, from TRACON Pharmaceuticals.

Charles Theuer

TRACON Pharmaceuticals, Inc. - President & CEO

Good morning. TRACON is a late clinical stage, pre-commercial company focused on oncology therapeutics for high unmet need populations. I'll make forward-looking statements today. I'll summarize four key investment highlights in today's presentation.

First is our potential best-in-class PD-L1 checkpoint inhibitor, envafolimab, potential best-in-class by virtue of the fact that it's the world's first approved subcutaneously administered checkpoint inhibitor. We're dosing envafolimab in the pivotal ENVASARC trial designed to transform the standard of care in refractory sarcoma.

We expect to file for approval next year, and I'll discuss important safety and efficacy data we released in December 2020 as well as additional updates expected this year. Our clinical pipeline is broad. Other than

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.